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Background: A Moroccan model for the FRAX tool to determine the absolute risk of osteoporotic fracture at 10
years has been established recently. The study aimed to assess the discriminative capacity of FRAX in identifying
women with prevalent asymptomatic vertebral fractures (VFs).
Methods: We enrolled in this cross-sectional study 908 post-menopausal women with a mean age of 60.9 years ±7.7
(50 to 91) with no prior known diagnosis of osteoporosis. Subjects were recruited from asymptomatic women selected
from the general population. Lateral VFA images and scans of the lumbar spine and proximal femur were obtained
using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genantsemiquantitative
(SQ) approach and morphometry. We calculated the absolute risk of major fracture and hip fracture with and without
bone mineral density (BMD)using the FRAX website.The overall discriminative value of the different risk scores was
assessed by calculating the areas under the ROC curve (AUC).
Results: VFA images showed that 179 of the participants (19.7%) had at least one grade 2/3 VF. The group of women
with VFs had a statistically significant higher FRAX scores for major and hip fractures with and without BMD, and lower
weight, height, and lumbar spine and hip BMD and T-scores than those without a VFA-identified VF. The AUC ROC of
FRAX for major fracture without BMD was 0.757 (CI 95%; 0.718-0.797) and 0.736 (CI 95%; 0.695-0.777) with BMD, being
0.756 (CI 95%; 0.716-0.796) and 0.747 (CI 95%; 0.709-0.785), respectively for FRAX hip fracture without and with BMD.
The AUC ROC of lumbar spine T-score and femoral neck T-score were 0.660 (CI 95%; 0.611-0.708) and 0.707 (CI 95%;
0.664-0.751) respectively.
Conclusion: In asymptomatic post-menopausal women, the FRAX risk for major fracture without BMD had a better
discriminative capacity in identifying the women with prevalent VFs than lumbar spine and femoral neck T-scores
suggesting its usefulness in identifying women in whom VFA could be indicated.
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Although assessing bone mass with dual-energy X-ray
absorptiometry (DXA) is the gold standard for osteo-
porosis diagnosis, studies have shown that most frac-
tures occur in individuals with a BMD T-score above
the WHO operational threshold for osteoporosis [1].
Recently, the use of clinical risk factors (CRFs) has
been shown to enhance the performance of BMD in
the prediction of hip and major osteoporotic fractures.
In addition to a prior fragility fracture, CRFs include
age, sex, body mass index (BMI), use of glucocorti-
coids, secondary osteoporosis, rheumatoid arthritis,
parental history of hip fracture, current smoking, and
alcohol intake of three or more units/day. The WHO
fracture risk assessment tool (FRAX) allows for estima-
tion of individual 10-year major osteoporotic and hip
fracture probabilities [2].
Vertebral fractures (VFs) are the most common type
of osteoporotic fractures in older adults. It has been
shown that VFs are usually asymptomatic (only one
fourth to one third of these fractures come to medical
attention) [3] and that women with a VF are four to five
times more likely to suffer another VF and are also
at increased risk for hip fracture and other nonspine
fractures compared with women without a VF; [4,5]
thus their detection remains an important challenge
for clinicians. Moreover, radiographically detected VFs
are associated with reduced quality of life, increased
morbidity and mortality [6]. Consequently, the identifi-
cation of asymptomatic VFs is of primordial importance
especially in patients without densitometric osteopor-
osis, a common situation where all experts agree to
recommend treatment [7,8]. Recently, Vertebral fracture
assessment (VFA), which is a method for imaging the
thoraco-lumbar spine using bone densitometers [9] has
been showed to have good accuracy and reliability. It can
easily be performed at the time of bone mineral density
(BMD) measurement, allowing integration of BMD and
VF information in the clinical care of patients evaluated
for osteoporosis [1]. Advantages of VFA compared with
spine radiographs include greater patient convenience
(VFA can be done in association with BMD testing by
DXA), smaller dose of ionizing radiation, and lower cost.
Previous studies report that, using VFA, around 90–95%
of vertebra are interpretable [10-12]. The majority of
uninterpretable vertebra occur above T7, [13,14] where
the prevalence of fracture is low, preserving the nega-
tive predictive value of VFA [15].
The performance characteristics of the FRAX tool
have been validated in many independent cohorts [16].
However, most if not all of these cohorts concerned
elderly women, usually over the age of 65 and have
mainly focused on hip fractures [17,18]. There is some
uncertainty as to whether this screening tool wouldhave the same performances in younger postmenopausal
women and in identifying asymptomatic VFs. Recently,
using VFA, we found that 19.7% of a cohort of asymptom-
atic women show evidence of moderate/severe VFs [19].
As a FRAX model was developed recently for Morocco
based on a large epidemiological study of hip fractures, [20]
we aimed in the present study to evaluate the performance
of FRAX scores in comparison with BMD measurement in
identifying women with prevalent asymptomatic VFs.
Methods
Subjects
This was a cross-sectional study conducted from june
2010 to march 2012 with menopausal women 50 years
old and over, living in the region of Rabat, recruited
from the general population through advertisements and
“word of mouth” in local hospitals. Both the rationale
and the study design have been described in details else-
where [19]. Briefly, nine hundred and eight consecutive
women who had no previous diagnosis of osteoporosis
were entered into the study. General exclusion criteria
were non-Caucasian origin and diseases, drugs, and other
major determinants known to affect bone metabolism.
Thus, we excluded subjects with gastrectomy, intestinal
resection, recent hyperthyroidism or hyperparathyroidism,
recent severe immobilization, treatment with corticoste-
roids (more than 3 months), breast cancer or aromatase
inhibitors. Our institutional review board approved this
study (Comité d’éthique et de recherche de l’hôpital
Militaire Mohammed V). The procedures of the study
were in accordance with the Declaration of Helsinki,
and formal local ethics committee approval was ob-
tained for the study (Comité d’éthique de la Faculté de
Médecine et de Pharmacie de Rabat). All the partici-
pants gave an informed and written consent. Each sub-
ject completed a standardized questionnaire designed to
document putative risk factors of osteoporosis. History
of fractures and lifestyle habits (alcohol consumption,
gymnastics or jogging/walking, smoking) were also re-
corded. Menstrual and reproductive history were assessed:
all patients were menopausal since at least one year.
Height and weight were measured in our centre before
DXA measurement, in light indoor clothes without shoes.
Body mass index (BMI) was calculated by dividing weight
in kilograms by height in meters squared.
BMD measurement
BMD was determined by a Lunar Prodigy Vision DXA
system (GE Healthcare, Madison, WI). The DXA scans
were obtained by standard procedures supplied by the
manufacturer for scanning and analysis. All BMD mea-
surements were carried out by 2 experienced technicians.
Daily quality control was carried out by measurement of
a Lunar phantom. At the time of the study, phantom
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sion expressed as the coefficient of variation percentage
was 0.08. Moreover, reproducibility has been assessed in
clinical practice and showed a smallest detectable differ-
ence of 0.04 g/cm2 (spine) and 0.02 (hips) [21,22]. Patient
BMD was measured at the lumbar spine (anteroposterior
projection at L1-L4) and at the femurs (i.e., femoral neck,
trochanter, and total hip). The World Health Organization
(WHO) classification system was applied, defining osteo-
porosis as T-score ≤ −2.5 and osteopenia as −2.5 < T-score
< −1. Study participants were categorized by the lowest
T-score of the L1–4 lumbar spine, femur neck, or total
femur.
Vertebral fracture assessment
All patients had a VFA imaging at the same time of their
BMD evaluation and all VFA scans were studied in a
separate occasion to assess the presence of VFs by the
same reader (IG) who was blinded to patient clinical
data. VFs was classified using a combination of Genant
[23] semiquantitative (SQ) approach and morphometry
in the following manner: each VFA image was inspected
visually by one clinician (IG), who is an experienced
reader of VFA, to decide whether it contained a fracture
in any of the visualized vertebrae and assigned a grade
based on Genant SQ scale, where grade 1 (mild) fracture
is a reduction in vertebral height of 20-25%, grade 2
(moderate) a reduction of 26-40%, and grade 3 (severe) a
reduction of over 40%. In case of doubt regarding frac-
ture grade, the vertebrae in question was measured
using built-in morphometry. Automatic vertebral recog-
nition by the software was used. Positioning of the six
morphometry points was modified only when the soft-
ware failed to correctly recognize vertebral heights.
Statistical analysis
Results are presented as means (SD) and categorical
variables are expressed as frequencies. To compare
patients with and without VFs, chi-square test and ana-
lysis of variance ANOVA were used firstly. To assess
and compare the discriminatory value for fracture of
FRAX and BMD in identifying women with VFs, we
used the Moroccan model for the FRAX algorithm
available at www.shef.ac.uk/FRAX to calculate individ-
ual 10-year probability of hip and major osteoporotic
fractures based on each woman’s clinical characteristics
with or without hip BMD measurement value. We assessed
the overall discriminative value of the different risk scores
by calculating the areas under the ROC curve (AUC).
Higher AUC values represent better prediction with the
models. We also assessed the sensitivity (proportion of
women with VFs who had been classified as high risk) and
specificity (proportion for women without VFs who had
not been classified as high risk) of each risk score forvarious definitions of the high-risk group based on dif-
ferent cut-offs. We also calculated the corresponding
positive and negative predictive values and the positive
likelihood ratios. The level for significance was taken
as p ≤0.05. Excel 2007 and SPSS 20.0 were used for
statistical analysis and STATA 12.0 was used for ROC
curves comparison (Stata Core, College Station, Texas).
The manuscript has adhered to the STROBE guidelines
for observational studies (Additional file 1).
Ethics committee
The local ethics committee of our hospital approved this
study.
Results
Patient demographics
In this series of 908 women, the mean ± SD (range) age,
weight and BMI were 60.9 ± 7.7 (50 to 91) years, 73.2 ±
13.2 (35 to 150) kgs and 29.8 ± 5.3 (14.5 to 50.8) kg/m2,
respectively (Table 1). According to the WHO classifica-
tion, 283 had osteoporosis (31.2%) and 402 had osteopenia
(44.3%). Only 4 women (0.4%) were current smokers. One
hundred and eighteen (12.9%) women reported a history
of traumatic peripheral fracture before the age of 50. None
of women reported a low impact fracture after 50.
Vertebral visualization and fracture identification on VFA
In these 908 women, 88.7% of vertebrae from T4–L4
and 99% from T8–L4 were adequately visualized on
VFA. The percentage of vertebrae not visualized at T4,
T5, and T6 levels was 74.1%, 49.2, and 16.1% respect-
ively. VFs were identified in 382 (42.1%): 203 (22.4%)
had grade 1 and 179 (19.7%) had grade 2 or 3. The
group of women with moderate/severe VFs had a statis-
tically significant higher age, parities, FRAX risk for
major fractures and hip fractures with and without
BMD and lower weight, height, and lumbar spine and
total hip BMD and T-scores than those without a VFA-
identified vertebral fracture (Table 1).
The AUCs are reported in Table 2 and depicted in
Figure 1. A model with no utility in predicting fracture
would have an AUC of 0.50 (i.e., no better than flipping
a coin or chance alone); AUC was greater than 0.50 for
all models. The highest AUC was observed for FRAX
risk without BMD which was significantly higher than
the AUC for lumbar spine (p = 0.0005) and femoral neck
(p = 0.048) T-scores. Analysis did not show significant
improvement when parity was added to FRAX risk with
or without BMD. None of our subjects had a FRAX risk
with or without BMD ≥20%.
We then compared the sensitivity for fracture of FRAX
risk (major fractures without BMD) and lumbar spine
and femoral neck T-scores for various definitions of the
high risk group based on percentile of their distribution
Table 1 Comparison between patients with and without vertebral fractures
Group 0: Women without
vertebral fractures N = 526
Group 1: Women with grade 1
vertebral fractures N = 203
Group 2: Women with grade 2 or 3
vertebral fractures N = 179
P-value 0 vs 2 P-value 0 vs 1 P-value 1 vs 2
Age (yrs): mean (SD) 59.1 (7.1) 60.7 (7.2) 66.5 (7.7) <0.0001 0.037 <0.0001
Weight (Kgs): mean (SD) 74.4 (13.0) 74.5 (14.3) 68.5 (11.4) <0.0001 NS <0.0001
Height (m): mean (SD) 1.57 (0.06) 1.55 (0.06) 1.55 (0.06) <0.0001 <0.0001 NS
Body Mass Index (Kg/m2): mean (SD) 30.0 (4.0) 30.7 (4.1) 28.4 (3.4) <0.001 NS <0.0001
Number of parity: mean (SD) 4.8 (2.3) 5.1 (2.5) 5.8 (3.1) <0.0001 NS NS
Years since menopause: mean (SD) 11.0 (8.2) 12.4 (8.5) 17.5 (9.4) <0.0001 NS <0.0001
Lumbar spine BMD (g/cm2): mean (SD) 0.998 (0.15) 0.945 (0.16) 0.873 (0.14) <0.0001 <0.0001 <0.0001
Lumbar spine T-score: mean (SD) -1.3 (1.2) -1.7 (1.3) -2.4 (1.2) <0.0001 0.025 <0.0001
Femoral neck BMD (g/cm2): mean (SD) 0.925 (0.14) 0.878 (0.13) 0.830 (0.12) <0.0001 0.002 0.049
Femoral neck T-score: mean (SD) -0.7 (1.0) -1.2 (1.1) -1.6 (1.0) <0.0001 0.003 0.003
Total hip BMD (g/cm2): mean (SD) 0.930 (0.14) 0.866 (0.13) 0.815 (0.12) <0.0001 0.003 0.002
Total hip T-score: mean (SD) -0.7 (1.0) -1.2 (1.1) -1.6 (1.0) <0.0001 0.003 0.002
T≤ −2.5 at anysite: n(%) 109 (20.7) 77 (37.9) 98 (54.7) <0.0001 <0.0001 <0.0001
FRAX major fracture without BMD 2.1 (1.2) 2.2 (1.2) 3.5 (1.7) <0.0001 NS <0.0001
FRAX hip fracture without BMD 0.4 (0.5) 0.4 (0.4) 1.0 (0.8) <0.0001 NS <0.0001
FRAX major fracture with BMD 2.2 (3.1) 2.5 (1.5) 3.4 (1.7) <0.0001 NS 0.002
FRAX hip fracture with BMD 0.4 (1.9) 0.5 (0.7) 0.9 (1.0) <0.001 NS 0.024
Data as mean (SD) or number (percent). We performed pairwise comparisons among the 3 groups using the Bonferoni test after an analysis of variance ANOVA.
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Table 2 Area Under Curve (AUC) of Receiver Operating Characteristics (ROC) for prediction of vertebral fractures using
FRAX tools and T-scores
VFs grade 2/3 VFs grade 1
AUC p AUC p
FRAX major fracture without BMD 0.757 (0.718 – 0.797) <0.0001 0.637 (0.591 – 0.683) <0.0001
FRAX hip fracture without BMD 0.756 (0.716 – 0.796) <0.0001 0.631 (0.585 – 0.677) <0.0001
FRAX major fracture with BMD 0.736 (0.695 – 0.777) <0.0001 0.662 (0.618 – 0.707) <0.0001
FRAX hip fracture with BMD 0.748 (0.710 – 0.786) <0.0001 0.662 (0.618 – 0.706) <0.0001
Lumbar spine T-score 0.660 (0.611 – 0.708)* <0.0001 0.610 (0.569 – 0.650) <0.0001
Femoral neck T-score 0.707 (0.664 – 0.751)* <0.0001 0.658 (0.621 – 0.695) <0.0001
FRAX major fracture without BMD with parity 0.697 (0.643 – 0.751)* <0.0001 0.632 (0.585 – 0.678) <0.0001
*Indicates p < 0.05 in comparison with the AUC of ROC of FRAX major fracture without BMD.
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fractures without BMDFRAX risk is set, for instance, at 3,
the sensitivity is approximately equal to 57%, specificity to
78%, the positive predictive value to 40% and the positive
likelihood ratio to 2.68.
Discussion
This study shows that FRAX risk with and without
BMD can predict prevalent asymptomatic osteoporotic
fractures in low risk postmenopausal women recruited
from general population. In this population, ROC c-
statistical analysis showed that the performance of FRAX
risk without BMD was better than that of lumbar spine
or femoral neck T-scores. Analysis of the BMD with theFigure 1 Receiver Operating Characteristic (ROC) curves for predictio
fracture; HF: hip fracture, LS: lumbar spine; FN: femoral neck.DXA technique for the axial skeleton has traditionally
been considered as the best predictive test known
to determine fragility VFs. Moreover, the strategy of
intervention for VFs prevention in medical practice has
been based on this test until the appearance of the
importance of other risk factors for fracture.
The FRAX tool is not designed to examine the risk of
asymptomatic VFs; however we performed this analysis
because of the importance of this kind of fractures in
the outcome of osteoporosis. It is now well established
that identification of VFs change the patient’s diagnostic
classification, estimation of fracture risk, and influence
the decision for a pharmacological intervention as treat-
ment of patients with prevalent VFs reduces the risk ofn of vertebral fractures using FRAX tools and T-scores. *MF: major
Table 3 Sensitivity, specificity, positive and negative predictive values and corresponding cut-offs of lumbar spine and
femoral neck T-scores and FRAX major fracture model without BMD for the prediction of grade 2/3 vertebral fractures
FRAX major fractures without BMD Lumbar spine T-score Femoral neck T-score
Cut-off Se Sp PPV NPV PLR Cut-off Se Sp PPV NPV PLR Cut-off Se Sp PPV NPV PLR
≥1% 99.4 13.4 21.8 98.9 1,15 ≤-1 82.8 35.2 23.7 89.4 1,28 ≤-1 81.0 45.5 26.5 90.8 1,49
≥2% 84.7 51.6 29.8 93.3 1,75 ≤-2 57.7 61.3 26.6 85.6 1,49 ≤-2 46.0 80.3 36.2 86.0 2,34
≥3% 57.1 78.7 39.4 88.3 2,68 ≤-2.5 47.2 76.9 33.2 85.7 2,04 ≤-2.5 27.6 91.2 43.3 83.8 3,14
≥4% 34.4 88.8 42.7 84.8 3,07 ≤-3 32.5 88.5 40.8 84.4 2,83 ≤-3 13.5 96.9 51.2 82.2 4,35
Se: sensitivity, Sp: specificity, PPV: positive predictive value, NPV: negative predictive value, PLR: positive likelihood ratio.
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the osteoporosis diagnostic cutpoint of -2.5. Thus,
regarding the important health consequences of osteo-
porotic VFs, together with the fact that most of them are
undiagnosed, emphasizes the need for developing better
methods to identify patients with asymptomatic VFs.
Few studies have focused on the predictive value of
FRAX risk for identifying women with asymptomatic
VFs. In Korea, So et al. in a cross-sectional study in-
cluding 194 patients found that FRAX underestimated
the risk of VFs compared to BMD [24]. Only two studies
did a longitudinal analysis. The first one was conducted in
3321 post-menopausal women with low bone mass (60%
of them having a femoral neck T score ≤ −2.5) from the
FIT (Fracture Intervention Trial) placebo group, of whom
30% had a radiographically detected vertebral fracture at
baseline [25]. The AUC was significantly greater for FRAX
with femoral neck BMD (AUC =0.71) than FRAX without
femoral neck BMD (AUC =0.68; p =0.002). The second
study was conducted in a cohort of postmenopausal
women (mean age 65.5 years), of whom 12.5% had a
radiographically detected VF at baseline and a mean lum-
bar spine T-score of −0.95, FRAX risk with and without
BMD discriminated patients with incident radiographic
VFs (FRAX risk with and without BMD predicted VFs
with an AUC of 0.66 and 0.62 respectively). This study
showed that the strongest risk factor of future VFs was the
combination of age, femoral neck BMD and the presence
of a radiographic VF at baseline [26].
FRAX has been included as a tool for identifying
postmenopausal women in recently updated guidelines
published by the NOF in the United States [27] and by
the National Osteoporosis Guideline Group [NOGG]),
in the UK [16,28]. The NOF recommends using FRAX
when the decision to treat or not to treat is uncertain.
It is primarily intended for postmenopausal women and
men 40 years of age and older who have T-scores be-
tween −1.0 and −2.5 and who are not on treatment, and
who have not had spine or hip fractures. The recom-
mended threshold for intervention is a 10-year hip frac-
ture probability ≥3% or major fracture (humerus, forearm,
hip or clinical vertebral fracture) probability ≥20%.
These NOF guidelines are difficult to apply in allcountries as they are based on cost-effectiveness that pro-
duce 35% prevention rate for 5 years according to fre-
quency, mortality and morbidity in the USA. Recently,
the Japanese committee recommended a cut-off value
of 15% on FRAX as treatment threshold for major
osteoporotic fractures in osteopenic patients as they
noted that FRAX underestimated fractures in the Jap-
anese population [29]. The FRAX scores observed in
our study were lower than these recommended
thresholds: they were likely influenced by the rela-
tively young age of the patients in this group (60.9 yr)
and the high BMI (29.8). Therefore, guidelines should be
adjusted according to the socioeconomic model of each
country.
As VFs are asymptomatic in two thirds of the cases,
our study shows that FRAX risk, even without BMD,
can discriminate subjects in whom testing BMD and
VFA at the same time would be worthy. Approximately
16% of these women (with osteopenia) and 8.5% of
women with normal BMD who otherwise may not have
been identified as being at greater fracture risk were
found to have unappreciated evident VFs (grade 2 and 3).
Thus, assessing BMD alone would have underestimate
the number of women needing osteoporosis medica-
tions (presence of VFs without osteoporosis).
We found that parity, which is not included in the
FRAX algorithm, was significantly associated to the
presence of VFs, independent of BMD and of the other
CRFs. This risk factor may be more specific of early
post-menopausal women than of older women. Hence,
we assessed whether adding parity to FRAX would improve
the ability to identify young postmenopausal women at high
risk of fracture. We found that the new score combining
parity and FRAX did not significantly improve the sen-
sitivity of FRAX, and did not have a better discriminant
value than lumbar spine T-score alone.
The assessment of fracture was carefully conducted
using standard procedures of acquisition, and standard
reading of all VFAs. All the morphometric assessments
were made by an experienced investigator after training
sessions. Before diagnosis of fracture, a non-osteoporotic
origin was considered for each deformity. The main
limitation lies in the procedures used to select subjects,
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ably healthier than the general population which also
probably explain the low FRAX scores observed in this
study. The Rabat population may not be adequately
representative of the whole population. However, since
the population living in the area of Rabat is a balanced
mixture of the various regions constitutive of the country,
we believe the impact on prevalence estimate is limited.
Conclusions
We showed that, in a cohort of low risk Moroccan post-
menopausal women recruited from the general popula-
tion, FRAX risk without BMD can identify those at
highest risk of prevalent asymptomatic osteoporotic VFs
suggesting its usefulness as an easy-to-use screening
tool in selecting women for VFA indication.
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